INVENTIVA SA - ADR (IVA) Stock Price & Overview
NASDAQ:IVA • US46124U1079
Current stock price
The current stock price of IVA is 5.5 USD. Today IVA is up by 3.77%. In the past month the price decreased by -17.04%. In the past year, price increased by 63.85%.
IVA Key Statistics
- Market Cap
- 1.142B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.42
- Dividend Yield
- N/A
IVA Stock Performance
IVA Stock Chart
IVA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 86.24% of all stocks.
IVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IVA. IVA has a bad profitability rating. Also its financial health evaluation is rather negative.
IVA Earnings
IVA Forecast & Estimates
16 analysts have analysed IVA and the average price target is 15.8 USD. This implies a price increase of 187.19% is expected in the next year compared to the current price of 5.5.
For the next year, analysts expect an EPS growth of 40.18% and a revenue growth -73.92% for IVA
IVA Groups
Sector & Classification
IVA Financial Highlights
Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -3.42. The EPS increased by 22.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA Ownership
IVA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 374.127B | ||
| AMGN | AMGEN INC | 15.58 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 11.02 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.66 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IVA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
IPO: 2017-02-15
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121 FR
CEO: Frederic Cren
Employees: 84
Phone: 33380447500
INVENTIVA SA - ADR / IVA FAQ
What does INVENTIVA SA - ADR do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Can you provide the latest stock price for INVENTIVA SA - ADR?
The current stock price of IVA is 5.5 USD. The price increased by 3.77% in the last trading session.
Does IVA stock pay dividends?
IVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IVA stock?
IVA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of INVENTIVA SA - ADR (IVA) based on its PE ratio?
INVENTIVA SA - ADR (IVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.42).
Should I buy IVA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IVA.
What is the market capitalization of IVA stock?
INVENTIVA SA - ADR (IVA) has a market capitalization of 1.14B USD. This makes IVA a Small Cap stock.